Photo: RNZ / Nate McKinnon
Healthcare and animal products company EBOS has posted another year of strong profit growth, with revenue exceeding $13 billion*.
Key numbers for the 12 months ended June compared with a year ago:
- Net profit $271.5m vs $253.4m
- Revenue $13.12b vs $12.24b
- Underlying profit from continuing operations $303.4m vs $281.8m
- Underlying margin 4.35% vs 4.43%
- FY dividend of NZ $1.18 per share vs $1.10 per share
- *All numbers quoted in Australian dollars unless otherwise stated AUD$1 = NZ$0.91035
The company's total net profit increased 7.2 percent on the previous year, while revenue increased 7.8 percent.
Chief executive John Cullity puts the performance down to strong growth in the company's community pharmacy and institutional healthcare divisions.
The healthcare businesses saw an underlying profit increase of 6 percent with strong market positions and infrastructure expansion and brand shareholding increases.
The animal care businesses had an underlying profit increase of 13.2 percent mainly driven by brands making products with high profit margins.
"Our confidence in our future growth strategies saw us make significant investments during the year in our operations and continue our expansion via acquisitions in both our Healthcare and Animal Care segments.
"The Group's diversification is a key strength as we navigate challenging domestic economic conditions and we have a strong pipeline of opportunities ahead of us as we continue to expand our operations outside New Zealand and Australia," said Cullity.